Bcl-2 [8], Bcl-xl [9], Survivin [11] and XIAP [10], regulated by NF-κB, act as prototype molecule at this crossroad and holds promise as target genes in CRC therapy [28, 29]. This evidence concerns the gene BCL2L1 and colorectal carcinoma.